Clozapine is the most effective therapy for treatment-resistant schizophrenia, yet adverse drug reactions (ADRs) limit its use. The concurrent ADR burden in outpatients and its relation to psychotropic polypharmacy, tobacco smoking and measured clozapine exposure has not been well characterised.
Method:
We conducted a retrospective, cross-sectional review of medical records for 360 adults receiving maintenance clozapine at a dedicated outpatient clinic. Adverse drug reactions (ADRs) were ascertained using a standardised patient checklist alongside clinical measures. We used multivariate logistic regression to estimate the association between antipsychotic polypharmacy and the presence of ADRs, and negative binomial regression to quantify its association with ADR burden. We conducted a log-linear model to evaluate dose-concentration compensation in tobacco smokers.
Results:
At the clinic visit, 89.6% had ⩾1 symptomatic ADR. The most prevalent were metabolic syndrome (71.8%), hypersalivation (64.7%) and tachycardia (61.2%). Antipsychotic augmentation (51.4%) was independently associated with ADRs (adjusted odds ratios [aOR] = 3.38, 95% confidence interval [CI] = 1.41–8.06) and a 28% higher ADR count per person (incidence-rate ratio [IRR] = 1.28, 95% CI = 1.11–1.48). Smokers received higher doses yet had lower plasma concentrations, suggesting incomplete dose compensation for CYP1A2 induction and had higher odds of antipsychotic augmentation (odds ratio [OR] = 2.50, 95% CI = 1.53–4.10).
Conclusion:
In maintenance clozapine care, persistent ADRs were common and were more frequent in patients receiving antipsychotic augmentation. Smokers were under-exposed to clozapine and were more likely to receive antipsychotic augmentation. Services should implement structured ADR surveillance and prioritise therapeutic drug monitoring-guided dose optimisation, particularly in smokers, before considering antipsychotic augmentation.
AlbitarOHarunSNZainalH, et al. (2020) Population pharmacokinetics of clozapine: A systematic review. Biomed Research International2020: 9872936.
2.
AmodeoGCrapanzanoCBaldiniI, et al. (2016) Clozapine-induced sinus tachycardia in patients treated with a slow titration schedule. European Neuropsychopharmacology2: S543–S544.
3.
BurkeMSebastianCS (1993) Treatment of clozapine sedation. The American Journal of Psychiatry150: 1900–1901.
4.
CentorrinoFBaldessariniRJKandoJC, et al. (1994) Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients. Journal of Clinical Psychopharmacology14: 119–125.
5.
ChenSYRavindranGZhangQ, et al. (2019) Treatment strategies for clozapine-induced sialorrhea: A systematic review and meta-analysis. CNS Drugs33: 225–238.
6.
CiprianiABosoMBarbuiC (2009) Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews8: CD006324.
7.
CohenHLoewenthalUMatarM, et al. (2001) Association of autonomic dysfunction and clozapine: Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. The British Journal of Psychiatry: The Journal of Mental Science179: 167–171.
8.
CorrellCAgidOCrespo-FacorroB, et al. (2022) A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs36: 659–679.
9.
CowardDM (1992) General pharmacology of clozapine. The British Journal of Psychiatry. Supplement17: 5–11.
10.
De las CuevasCSanzEJde LeonJ (2024) Pharmacovigilance in action: Utilizing VigiBase data to improve clozapine safety. Patient Preference and Adherence18: 2261–2280.
11.
De LeonJSanzEJDe las CuevasC (2020a) Data from the World Health Organization’s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophrenia Bulletin46: 1–3.
12.
de LeonJSchoretsanitisGKaneJM, et al. (2020b) Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists12: e12384.
13.
De LeonJSchoretsanitisGSmithRL, et al. (2022) An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry55: 73–86.
14.
EdwardsIRAronsonJK (2000) Adverse drug reactions: Definitions, diagnosis, and management. The Lancet356: 1255–1259.
15.
Every-PalmerSEllisPM (2017) Clozapine-induced gastrointestinal hypomotility: A 22-year bi-national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs31: 699–709.
16.
Every-PalmerSEllisPMNowitzM, et al. (2017) The porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: A pre-and post-treatment study. CNS Drugs31: 75–85.
17.
Every-PalmerSNowitzMStanleyJ, et al. (2016) Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: A cross sectional study. EBiomedicine5: 125–134.
18.
FentonCKangC (2023) Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management. Drugs & Therapy Perspectives: For Rational Drug Selection and Use39: 107–113.
19.
GaertnerIGaertnerHJVontheinR, et al. (2001) Therapeutic drug monitoring of clozapine in relapse prevention: A five-year prospective study. Journal of Clinical Psychopharmacology21: 305–310.
20.
HaringCMeiseUHumpelC, et al. (1989) Dose-related plasma levels of clozapine: Influence of smoking behaviour, sex and age. Psychopharmacology99: S38–S40.
21.
Hinze-SelchDMullingtonJOrthA, et al. (1997) Effects of clozapine on sleep: A longitudinal study. Biological Psychiatry42: 260–266.
22.
HommersLScharlMHefnerG, et al. (2018) Comedication of valproic acid is associated with increased metabolism of clozapine. Journal of Clinical Psychopharmacology38: 188–192.
23.
HonerWGThorntonAEChenEY, et al. (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine354: 472–482.
24.
HydeNDoddSVenugopalK, et al. (2015) Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: A retrospective observational, clinical cohort study. Current Drug Safety10: 125–131.
25.
IqbalEGovindRRomeroA, et al. (2020) The side effect profile of clozapine in real world data of three large mental health hospitals. PLoS ONE15: e0243437.
26.
IsmailZWesselsAMUchidaH, et al. (2012) Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry20: 53–60.
27.
KaneJHonigfeldGSingerJ, et al. (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry45: 789–796.
28.
KatzPODunbarKBSchnoll-SussmanFH, et al. (2022) ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Official Journal of the American College of Gastroenterology| ACG117: 27–56.
29.
KellyDLMcMahonRPLiuF, et al. (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: A retrospective cohort study. The Journal of Clinical Psychiatry71: 304–311.
30.
LähteenvuoMTiihonenJ (2021) Antipsychotic polypharmacy for the management of schizophrenia: Evidence and recommendations. Drugs81: 1273–1284.
31.
LallyJDochertyMJMacCabeJH (2016) Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database of Systematic Reviews2016: CD011566.
32.
LandRSiskindDMcArdleP, et al. (2017) The impact of clozapine on hospital use: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica135: 296–309.
33.
LaneHYChangYCChangWH, et al. (1999) Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics. The Journal of Clinical Psychiatry60: 36–40.
34.
LégaréNGrégoireCADeBenedictisL, et al. (2013) Increasing the clozapine: Norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Medical Hypotheses80: 689–691.
35.
LeggeSEHamshereMHayesRD, et al. (2016) Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. Schizophrenia Research174: 113–119.
36.
LenkHÇLøvslettenSmithRO’ConnellKS, et al. (2023) Impact of NFIB and CYP1A variants on clozapine serum concentration: A retrospective naturalistic cohort study on 526 patients with known smoking habits. Clinical and Translational Science16: 62–72.
37.
LiebermanJASaffermanAZPollackS, et al. (1994) Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. The American Journal of Psychiatry151: 1744–1752.
38.
MayerovaMUstohalLJarkovskyJ, et al. (2018) Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatric Disease and Treatment: 1535–1543.
39.
MeltzerHYAlphsLGreenAI, et al. (2003) Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Archives of General Psychiatry60: 82–91.
40.
MeltzerHYBastaniBKwonKY, et al. (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology99: S68–S72.
41.
MeltzerHYBurnettSBastaniB, et al. (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital & Community Psychiatry41: 892–897.
42.
MillerCHMohrFUmbrichtD, et al. (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine. The Journal of Clinical Psychiatry59: 69–75.
43.
MylesNMylesHXiaS, et al. (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatrica Scandinavica138: 101–109.
44.
National Institutes of Health NIo (2001) ATP III guidelines at-a-glance quick desk reference. NIH publication 01–3305.
45.
NemaniKLGreeneMCUlloaM, et al. (2019) Clozapine, diabetes mellitus, cardiovascular risk and mortality: Results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. Clinical Schizophrenia & Related Psychoses12: 168–176.
46.
NgCHChongSALambertT, et al. (2005) An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International Clinical Psychopharmacology20: 163–168.
47.
NorthwoodKPearsonEArnautovskaU, et al. (2023) Optimising plasma clozapine levels to improve treatment response: An individual patient data meta-analysis and receiver operating characteristic curve analysis. The British Journal of Psychiatry: The Journal of Mental Science222: 241–245.
48.
PalegoLBiondiLGiannacciniG, et al. (2002) Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: Influence of patient-related variables. Progress in Neuro-Psychopharmacology & Biological Psychiatry26: 473–480.
49.
PeacockLSolgaardTLublinH, et al. (1996) Clozapine versus typical antipsychotics a retro-and prospective study of extrapyramidal side effects. Psychopharmacology124: 188–196.
50.
Ramos PerdiguésSSaurasQuecutiRManéA, et al. (2016) An observational study of clozapine induced sedation and its pharmacological management. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology26: 156–161.
51.
PolcwiartekCNielsenJ (2016) The clinical potentials of adjunctive fluvoxamine to clozapine treatment: A systematic review. Psychopharmacology233: 741–750.
52.
PotkinSGBeraRGulasekaramB, et al. (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. The Journal of Clinical Psychiatry55: 133–136.
53.
RemingtonGAgidOFoussiasG, et al. (2013) Clozapine and therapeutic drug monitoring: Is there sufficient evidence for an upper threshold?Psychopharmacology225: 505–518.
54.
Rostami-HodjeganAAminAMSpencerEP, et al. (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology24: 70–78.
55.
ShiraziAStubbsBGomezL, et al. (2016) Prevalence and predictors of clozapine-associated constipation: A systematic review and meta-analysis. International Journal of Molecular Sciences17: 863.
56.
SiskindDMcCartneyLGoldschlagerR, et al. (2016a) Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science209: 385–392.
57.
SiskindDSidhuACrossJ, et al. (2020) Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. The Australian and New Zealand Journal of Psychiatry54: 467–481.
58.
SiskindDJLeungJRussellAW, et al. (2016b) Metformin for clozapine associated obesity: A systematic review and meta-analysis. PLoS ONE11: e0156208.
59.
SmithRLWollmannBMKyllesøL, et al. (2022) Effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia. Journal of Clinical Psychopharmacology42: 43–50.
60.
SrisurapanontMSuttajitSManeetonN, et al. (2015) Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials. Journal of Psychiatric Research62: 38–47.
61.
StryjerRTiminskyIReznikI, et al. (2009) β-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: A retrospective study. Clinical Neuropharmacology32: 290–292.
62.
TanMSAHonarparvarFFalconerJR, et al. (2021) A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology238: 615–637.
63.
TangYLMaoPLiFM, et al. (2007) Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. British Journal of Clinical Pharmacology64: 49–56.
64.
TanzerTDBrouardTPraSD, et al. (2022a) Treatment strategies for clozapine-induced hypotension: A systematic review. Therapeutic Advances in Psychopharmacology12: 1092931.
65.
TanzerTDPhamBWarrenN, et al. (2024) Overcoming clozapine’s adverse events: A narrative review of systematic reviews and meta-analyses. Expert Opinion on Drug Safety23: 811–831.
66.
TanzerTDWarrenNMcMahonL, et al. (2022b) Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: A systematic review. CNS Spectrums2022: 1–12.
67.
TaylorDCahillCWallangP, et al. (2023) Predicting clozapine dose required to achieve a therapeutic plasma concentration: A comparison of a population algorithm and three algorithms based on gene variant models. Journal of Psychopharmacology37: 1030–1039.
68.
ThornCFMüllerDJAltmanRB, et al. (2018) PharmGKB summary: Clozapine pathway, pharmacokinetics. Pharmacogenetics and Genomics28: 214–222.
69.
UlrichSBaumannBWolfR, et al. (2003) Therapeutic drug monitoring of clozapine and relapse: A retrospective study of routine. International Journal of Clinical Pharmacology and Therapeutics41: 3–13.
70.
van der HorstMZMeijerYdeBoerN, et al. (2023) Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research330: 115539.
71.
VarmaSBisharaDBesagFM, et al. (2011) Clozapine-related EEG changes and seizures: Dose and plasma-level relationships. Therapeutic Advances in Psychopharmacology1: 47–66.
72.
VermeulenJMvan RooijenGvan de KerkhofMP, et al. (2019) Clozapine and long-term mortality risk in patients with schizophrenia: A systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophrenia Bulletin45: 315–329.
73.
WagnerEKaneJMCorrellCU, et al. (2020a) Clozapine combination and augmentation strategies in patients with schizophrenia: Recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin46: 1459–1470.
74.
WagnerEMcMahonLFalkaiP, et al. (2020b) Impact of smoking behavior on clozapine blood levels: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica142: 456–466.
75.
XiangYQZhangZJWengYZ, et al. (2006) Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophrenia Research83: 201–210.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
